24/7 Customer Support
Japan pet cancer therapeutics market was valued at US$ 14.4 Million in 2022 and is projected to reach a valuation of US$ 26.1 Million by 2031 at a CAGR of 7.3% during the forecast period 2023-2031.
The demand for pet cancer treatment in Japan is growing rapidly. According to a report by the Japanese Animal Hospital Association, the number of pets treated for cancer in Japan has increased by more than 20% in the past five years. There are several reasons for this increase in demand. First, the number of pet ownership is increasing in Japan. In 2019, there were an estimated 7.1 million households with pets in Japan, which is a 1.5 million increase from 2010. With more pets comes a higher chance of developing cancer. Second, pets are living longer due to advances in veterinary medicine. This means that they are more likely to develop cancer as they age.
Today, Japanese pet owners are becoming more aware of the importance of early detection and treatment of cancer in the pet cancer therapeutics market. Thanks to social media and the internet, pet owners are able to learn about the latest advances in cancer treatment and make informed decisions about their pet's care. With the growing demand for pet cancer treatment, many vets are now offering specialized services and treatments. Some vets have even opened up dedicated pet cancer clinics. While the cost of treatment can be high, many pet owners are willing to pay anything to give their beloved furry friend a fighting chance.
Some of the major players in the Japan pet cancer therapeutics market are Boehringer Ingelheim International GmbH, Zoetis Inc., AB Science, Elanco Animal Health Incorporated, ELIAS Animal Health LLC, Karyopharm Therapeutics, Regeneus Ltd., Rhizen Pharmaceuticals AG, Pfizer Inc., Torigen Pharmaceuticals Inc, Virbac, Sumitomo Pharma Animal Health Co., Nippon Zenyaku Kogyo Co. Ltd. and Other Prominent Players.
Astute Analytica’s Analysis of Japan Pet Cancer Therapeutics Market
Cancer is the leading cause of death in dogs and cats in Japan, and the pet cancer therapeutics market is expected to grow to 26.1 million by 2031. Our analysis shows that the market is driven by a number of factors, including an aging pet population, a growing awareness of pet health issues, and a preference for natural and holistic treatments. The most popular type of pet cancer treatment in Japan is surgery, followed by radiation therapy and chemotherapy. However, there is a growing trend towards less invasive and more natural treatments, such as acupuncture, herbal medicine, and homeopathy.
In terms of marketing, the Japan pet cancer therapeutics market is still in its infancy in Japan. However, there is potential for growth, especially in online channels. For example, our research shows that 47% of dog owners and 34% of cat owners would be willing to purchase pet cancer treatments online. As the pet cancer treatment industry continues to grow in Japan, it is important for companies to keep up with the latest trends and technologies. This analysis can help businesses make informed decisions about where to focus their resources in order to stay ahead of the competition.
The therapy segment in the Japan pet cancer therapeutics market is classified into chemotherapy, immunotherapy, targeted therapy, and combination therapy. The chemotherapy segment is currently dominating market and is expected to keep its dominance in the years to come thanks to quick responses of the pets to the treatment.
Apart from this, there are a number of reasons why chemotherapy is such a popular choice among pet owners in Japan. First, chemotherapy is relatively affordable compared to other cancer treatments. Second, it is generally considered to be less invasive than other options such as surgery or radiation therapy. Third, chemotherapy can be administered on an outpatient basis, which is convenient for busy pet owners. Of course, chemotherapy is not without its side effects. The most common side effects include nausea, vomiting, diarrhea, and fatigue in the pet cancer therapeutics market. However, these side effects can generally be managed with proper supportive care from a veterinarian.
Rout of Administration
Based on rout of administration, the market is further classified into oral and injection. In this, oral segment held the largest share of the Japan pet cancer therapeutics market and is expected to continue dominating the market growth in future.
This is because the oral route is more convenient and less invasive than other routes of administration such as intravenous or intramuscular injection. The oral route of drug administration allows the pet to be treated in a more natural way, as they would normally take their medications by mouth. This route also avoids the potential side effects associated with other routes of administration, such as pain at the injection site. Oral administration of drugs is also easier to monitor, as pet owners can simply observe whether their pet is taking the medication or not. This is important, as some pets may refuse to take their medication if it is injected or given in another way. Overall, the oral route of drug administration is the most preferred in the treatment of pet cancer in Japan due to its convenience, safety, and effectiveness.
Based on species, the pet cancer therapeutics market is classified as under dogs, cats and others. The prevalence of cancer amongst dogs is much higher than in cats. According to the Flint Animal Cancer Center, one in every four dogs is most likely to suffer from cancer. Hence, high occurrence of cancer among dogs is propelling the market growth.
There are many factors that contribute to the high prevalence of cancer in dogs in Japan. The country has a high population density, which means that there are more dogs living in close proximity to one another. This increases the chances of transmission of the disease. Additionally, the Japanese diet is heavy in processed meats and fish, which contain carcinogens that can increase the risk of cancer. There are several types of cancer that are particularly prevalent in dogs in pet cancer therapeutics market. One is lymphoma, which is a cancer of the lymphatic system. Lymphoma is relatively common in all dogs, but the incidence is much higher in Japan. Another common type of cancer in Japanese dogs is gastrointestinal cancer, which includes cancers of the stomach, intestines, and rectum. Gastrointestinal cancer is also relatively common in all dogs, but the incidence is again much higher in Japan.
Based on the therapeutic application, the market is bifurcated into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer. Most common application is lymphoma and mast cell cancer.
Lymphoma is a very common form of cancer in dogs. Canine lymphoma is common in middle-aged to old pets. There are more than 30 different types of lymphoma which dogs can develop, the most common types of dog lymphoma are, multicentric, alimentary, mediastinal and extranodal lymphoma.
Distribution Channel Insights:
Based on distribution channel, the pet cancer therapeutics market is classified into veterinary hospitals & clinical pharmacies, online pharmacies, and retail pharmacies.
It is no secret that the cost of pet cancer treatment can be extremely expensive. In Japan, the average cost of cancer treatment is around $10,350. This is a significant amount of money for most families, and it can be a huge financial burden. Many pet owners in Japan prefer to take their pets to offline channels for cancer therapeutics. There are a few reasons for this. First, offline channels usually have a lower cost of treatment. Second, pet owners can often get guidance and support from offline channel staff. Finally, many pet owners feel more comfortable taking their pets to offline channels because they can talk to staff and get more information about the treatment options.
However, there are also some drawbacks to taking cancer therapeutics from offline channels in the Japan pet cancer therapeutics market. One downside is that pet owners may have to travel to get to the nearest offline channel. Additionally, not all offline channels offer the same quality of care. Some pet owners may also prefer the convenience of online channels.
Overall, pet owners in Japan seem to prefer taking cancer therapeutics from offline channels. The main reasons for this preference are lower costs, better guidance and support, and more comfort. However, there are some drawbacks to using offline channels, such as travel time and distance, and the possibility of lower quality care.
Segmentation Overview of the Japan Pet Cancer Therapeutics Market
By Rout Of Administration
By Distribution Channel
The market size of the Japan Pet Cancer Therapeutic Market was valued at US$ 14.4 Mn in 2022.
The market is registered to grow at a CAGR of 7.3% during 2023-2031.
Rising adoption of pets and rising number of pet insurance in Japan are the factors triggering growth of the Pet Cancer Therapeutic market.
Shrinking size of pharma sector in Japan as compared to Western countries are the factors restraining market growth.
Development of new drugs and therapeutic treatment is current trend in the market.
The various segmentations considered to analyze the Japan Pet Cancer Therapeutic Market are based on therapy, route of administration, species, application, distribution channel.
Rising life expectancies of pet in Japan
Chemotherapy segment dominated the Japan Pet Cancer Therapeutic Market in 2022.
Veterinary Hospitals & Clinical Pharmacies distribution channel held the highest segmental share in 2022.
Lymphoma dominated the Japan Pet Cancer Therapeutic Market in 2022.
Boehringer Ingelheim International GmbH, Zoetis, NIPPON ZENYAKU KOGYO CO., LTD., Sumitomo Pharma Animal Health Co., Elanco Animal Health Incorporated are the key players analyzed in the Japan Pet Cancer Therapeutic market.
The pandemic had a slightly negative impact on the Japan Pet Cancer Therapeutic Market, with a 1.22% drop in Y-O-Y growth of 2019-2020.